Last reviewed · How we verify

NCT03172429

Cerebral Tissue Oxygenation in Highlanders/Lowlanders

Completed Last updated 16 August 2019
What this trial tests

trial in High Altitude Pulmonary Hypertension in 79 participants. Completed in 16 August 2017.

Timeline
24 May 2017
Primary endpoint
16 August 2017
16 August 2017

Quick facts

Lead sponsorUniversity of Zurich
StatusCompleted
Study typeOBSERVATIONAL
Enrollment79
Start date24 May 2017
Primary completion16 August 2017
Estimated completion16 August 2017
Sites1 location across Kyrgyzstan

Conditions studied

Sponsor

University of Zurich

Who can join

16 and older, any sex, with High Altitude Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the current study is to evaluate the cerebral tissue oxygenation of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To this end, the investigators will invite the same highlanders who participated in the study in 2012 to undergo follow-up examinations in 2017, in order to allow comparisons of current results with baseline data from 2012.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for High Altitude Pulmonary Hypertension

Currently open trials in the same condition.

Other University of Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03172429.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing